Cardiome Amends Term Loan Agreement with CRG-Managed Funds
Cardiome Pharma has amended its term loan agreement with CRG-managed funds to provide up to $50 million of available borrowing capacity.
Cardiome Pharma has amended its term loan agreement with CRG-managed funds to provide up to $50 million of available borrowing capacity.
Viewray Technologies entered into an amendment with CRG to expand the borrowing capacity available under its term loan agreement by $15 million to $65 million.
BioDelivery Sciences closed a senior credit facility with affiliates of CRG, a healthcare-focused investment firm, to retire its existing credit facility and provide additional working capital for the company.
Endoceutics, a private Quebec City-based biopharma company, entered into a long-term $85 million senior credit facility with CRG, a healthcare-focused investment firm.
T2 Biosystems entered into a $50 million debt facility agreement with CRG, which consists of an initial draw of $40 million and the ability to borrow an addition $10 million through July 2018.
Omeros completed the initial funding under its senior secured credit facility with affiliates of CRG, a healthcare-focused investment firm, consisting of an $80 million term loan.
Tandem Diabetes Care has amended its term loan facility with Capital Royalty Partners II, which will provide the company access to $50 million in addition to the $30 million borrowed from CRG in January 2013.
Benvenue Medical completed a $60 million round of financing encompassing a $23 million in equity and $37 million in debt financing provided by CRG, a healthcare focused investment management firm.
Silk Road Medical has received up to $57 million in equity and debt funding. CRG led the debt financing and also participated as an equity investor.
GenomeDx Biosciences said it secured expansion financing from healthcare investment firm CRG in the form of a secured term loan.